scispace - formally typeset
T

Timo Stellfeld

Researcher at Bayer HealthCare Pharmaceuticals

Publications -  34
Citations -  844

Timo Stellfeld is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Bombesin & Medicine. The author has an hindex of 14, co-authored 31 publications receiving 774 citations. Previous affiliations of Timo Stellfeld include Stanford University & Bayer Schering Pharma AG.

Papers
More filters
Journal ArticleDOI

Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks.

TL;DR: This study demonstrates the applicability of the silicon-based one-step n.c. radiolabeling method for the synthesis of new 18F-labeled bombesin derivatives for the PET imaging of GRPr expression in prostate tumor.
Journal ArticleDOI

Direct One-Step18F-Labeling of Peptides via Nucleophilic Aromatic Substitution

TL;DR: The results of the one-step [18F]-fluorination of tetrapeptides and bombesin peptides show that the direct 18F-labeling of peptides is feasible under mild conditions and in good radiochemical yields.
Journal ArticleDOI

18F-Radiolabeling of Aromatic Compounds Using Triarylsulfonium Salts

TL;DR: A new method for the 18F-radiolabeling of aromatic compounds based on the aromatic nucleophilic substitution (SNAr) reaction using triarylsulfonium salts has been developed and indicates that sulfonium ions have the potential to be optimized for labeling nonactivated and deactivated aryl rings that have Hammett σP substituent constants greater than –0.170.